Cutiss Presents Positive One-Year Results for DenovoSkin

Schlieren ZH – Cutiss presents the results of a one-year study on its denovoSkin skin substitute. The data from the Phase 2 clinical trial in adult and adolescent patients with severe burns are considered positive.

Cutiss AG, which specialises in skin transplants, provides positive data after one year in adult and adolescent patients with severe burns from the Phase 2 clinical trial with its main product denovoSkin. Following the positive primary endpoint in the first quarter of 2023, the long-term safety and quality of the scars were evaluated in the one-year study, according to a press release.

The data and results of phase 2 to date show that the denovoSkin skin transplant, with two layers (epidermis and dermis), can safely cover severe burn wounds, while significantly sparing the patient's healthy donor sites and improving the overall quality of the scars compared to the patient's standard treatment, the report continues.

"The achievements of the last decade have put us in the middle of an important paradigm shift in the treatment of burns: from mortality, which used to be the main concern, to areas that focus on the quality of life of burn survivors," Professor Martin Meuli, Chairman of the Board of Cutiss, is quoted. Conceptualizing the epidermis as "life" and the dermis as "quality of life" is perhaps simplistic, "but still useful to understand the impact that denovoSkin can potentially have in burn surgery," Meuli continued.

Cutiss was founded in 2017 as a spin-off of the University of Zurich (UZH) and is based at the Bio-Technopark Schlieren-Zurich. ce/gba

View full article